AD
ADMA Biologics
ADMA · NASDAQ
$9.96 -0.80% (-$0.08)
1M +7.77%
Market Cap $2.35B
P/E Ratio 13.88x
Div. Yield -
ROE 39.59%
Bulios Fair Price
$5.84
41.4% downside
Current Price
$9.96
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ADMA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
6/9Valuation
66 /100
Fair P/S 4.58x
P/E 13.88x
P/B 5.75x
Growth
100 /100
Growing Book val. growth 46.45%
Rev. growth 49.05%
FCF growth N/A
Profitability
100 /100
Strong Op. margin 42.26%
Gross margin 64.71%
FCF margin 22.74%
Quality
94 /100
Excellent ROA 24.69%
ROIC 27.55%
Asset turnover 0.75x
Debt
95 /100
Low Int. coverage 25.53x
Debt/Equity 0.50x
Net debt/EBITDA 0.29x
Stability
42 /100
Moderate EPS volatility 407.63%
Beta 0.77x
Profitable years 2
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ADMA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Adam S. Grossman
Employees
644
Headquarters
Ramsey
Upcoming events
04 NOV
Earnings
Upcoming earnings report